RTP Mobile Logo
Select Publications

Antonia SJ et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017;377(20):1919-29. Abstract

Gray JE et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC — Update from PACIFIC. J Thorac Oncol 2020;15(2):288-93. Abstract

Han G et al. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: Is EGFR mutation associated with a higher incidence of brain metastasis? Oncotarget 2016;7(35):56998-7010. Abstract

Li Y-S et al. Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol 2016;11(11):1962-9. Abstract

Mack F et al. Therapy of leptomeningeal metastasis in solid tumors. Cancer Treat Rev 2016;43:83-91. Abstract

Nakagawa K et al. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC). ASCO 2019;Abstract 9000.

Piotrowska Z et al. ECOG-ACRIN 5162: A Phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions. ASCO 2020;Abstract 9513.

Ramalingam SS et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020;382(1):41-50. Abstract

Rangachari D et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 2015;88(1):108-11. Abstract

Reungwetwattana T et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol 2018;JCO2018783118. Abstract

Socinski MA et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018;378(24):2288-301. Abstract

Soria JC et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378(2):113-25. Abstract

Stanic K et al. Brain metastases in lung adenocarcinoma: Impact of EGFR mutation status on incidence and survival. Radiol Oncol 2014;48(2):173-83. Abstract

Toi Y et al. A randomized phase II study of osimertinib with or without bevacizumab in advanced lung adenocarcinoma patients with EGFR T790M mutation (West Japan Oncology Group 8715L). ESMO 2020;Abstract 1259O.

Tsuboi M et al. Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence. ESMO 2020;Abstract LBA1.

Wu YL et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020. Abstract

Yang JCH et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study. J Clin Oncol 2020;38(6):538-47. Abstract

Yu H et al. Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: A phase 1/2 single-group open-label trial. JAMA Oncol 2020;6(7):1048-54. Abstract